The effect of tranexamic acid on blood loss after vaginal delivery

Jayaraman Nambari M¹,*, Keerthi Somu²

¹Professor, ²Junior Resident, Dept. of Obstetrics and Gynaecology, Kasturba Medical College, Manipal.

*Corresponding Author: Jayaraman Nambari M
Email: drramnambiar@gmail.com

Received: 12th October, 2018
Accepted: 16th November, 2018

Abstract
Objectives: To find out the effect of tranexamic acid on blood loss after vaginal delivery.
Materials and Methods: In this observational study, 100 women with a singleton pregnancy were allocated to receive one gram intravenous tranexamic acid or no drug in addition to 10 units of oxytocin after delivery of the fetus. Blood loss calculated by a graduated blood bag. Pre and post-delivery hemoglobin and hematocrit are determined.
Results: The mean blood loss (245ml vs 327 ml, p=<0.01) was significantly lower in the study group compared to the control group. The post-delivery hemoglobin and hematocrit (11.4gm/dl, 35% vs 10.5gm/dl, 32%, p<0.01) was significantly lower in study group compared to control group.
Conclusions: Tranexamic acid helps to reduce the amount of blood loss in vaginal delivery.

Keywords: Postpartum hemorrhage, Tranexamic acid, Vaginal delivery.

Introduction
Labor is a physiological process, but it is often associated with morbidity and mortality. Bleeding is a common cause of maternal death. Postpartum hemorrhage is defined as blood loss of 500 mL or more after delivery within 24 hours.¹ The foremost cause of maternal mortality is postpartum hemorrhage. Incidence of PPH is reported as 2%-4% after vaginal delivery and 6% after cesarean section. According to India Sample registration scheme (SRS) 2001-2003, PPH accounts 38% of maternal deaths.² By timely and appropriate management, the deaths from PPH can be avoided. The most common use being prophylactic uterotonics in third stage of labor. The pathophysiology of PPH involves mechanical and clotting mechanism. By using prohemostatic drugs like tranexamic acid a biochemical hemostatic effect can be expected. Tranexamic acid decreases the lysis of fibrin clots.³,⁴ Since 1960s, tranexamic acid, an anti-fibrinolytic agent has been used in different medical and surgical conditions. In a systematic review by Cochrane review it is recommended that more studies are needed to assess the efficacy of tranexamic acid to reduce blood loss.⁵ Efficacy of tranexamic acid has been evaluated in obstetrics and gynecology in reducing blood loss in conditions like menorrhagia, myomectomy,⁶ postpartum blood loss in elective cesareansections,⁷ ovarian tumors.⁸ Many studies have suggested that tranexamic acid is reducing blood loss after delivery.⁹,¹¹ Tranexamic acid is a very easily available drug and is cheap. Though there are concerns about thrombosis with the use of this drug there are many studies which suggested that the drug can be safely used without the risk of thrombosis.¹²,¹³ Decreasing the blood loss after delivery would help a long way in reducing maternal mortality. The purpose of this study was to find out the efficacy of tranexamic acid in reducing blood loss after delivery.

Materials and Methods
This study is prospective observational study, carried out over a period from August 2015 to August 2017, in the department of Obstetrics and Gynecology, in a tertiary care hospital. Prior to enrolment ethical committee clearance was obtained from Hospital Ethical Committee (IEC: 551/2015). Prior to enrolment, written informed consent was attained from all women participated in the study. All women were explained purpose of study and consent was taken in the language that they understand.

The eligible participants were all women aged 18-35 years with a term singleton pregnancy with cephalic presentation who had vaginal delivery. Patients with grand multiparity (parity>5), uterine surgery and uterine myoma were excluded from the study. Patients with known coagulation disorders. Anaemia, were also excluded from the study. Patients who underwent cesarean section were excluded from the study.

Hundred pregnant women entered the study. There were 50 subjects in control group and 50 in the study group. Patients in labor either spontaneous or induced were enrolled for the study. Patients with aforementioned exclusion criteria are not included. A structured proforma was designed to record the demographic details, past history and delivery details of all the subjects enrolled for the study. The pre-delivery hemoglobin levels and PCV were noted in each patient. Monitoring of labor done. Ten units Inj. Oxytocin 10 units was given to the mother IM within 1 min of delivery of the baby, followed by Inj. Tranexamic acid 1 gram slow IV in study group. In control group no additional drug was given apart from Inj. Oxytocin. A calibrated blood collecting bag was used to measure the blood loss. The calibrated bag was placed under the patients buttock to measure the blood loss. Patients were continuously monitored for clinical signs of thrombosis.
or other complications. Complications if any, noted. Post-delivery Hemoglobin levels and PCV were noted 24 hours after delivery. Blood loss and change in Hemoglobin levels and PCV were noted in each group.

**Results**

All 100 pregnant women allocated into the groups were analyzed (Fig. 1). The two groups matched in terms of socio-demographic, and also in terms of reproductive, delivery characteristics, newborn weight. The demographic characteristics of the recruited women are shown in Table 1. The amount of blood loss in study and control group was 245ml and 327 ml respectively which is significant (P<0.01). There was a significant difference in the post-delivery Hemoglobin (P<0.01) and PCV (P < 0.01) between the groups. The difference of Hemoglobin and PCV decline in the study group and in control group was statistically significant (P <0.01). The results are showed in Table 2. No adverse effects were observed with the use of tranexamic acid in the study.

**Table 1:** Demographic and obstetric characteristics of participants by group

<table>
<thead>
<tr>
<th></th>
<th>N=100</th>
<th>Study group N=50</th>
<th>Control group N=50</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years</td>
<td>27.76±3.56</td>
<td>26.82±2.63</td>
<td>0.13</td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>26.57±2.2</td>
<td>25.8±1.62</td>
<td>0.43</td>
<td></td>
</tr>
<tr>
<td>Primipara</td>
<td>28</td>
<td>39</td>
<td>0.39</td>
<td></td>
</tr>
<tr>
<td>Multipara</td>
<td>22</td>
<td>11</td>
<td>0.79</td>
<td></td>
</tr>
<tr>
<td>Sponatenous labour</td>
<td>39</td>
<td>41</td>
<td>0.32</td>
<td></td>
</tr>
<tr>
<td>Induced labour</td>
<td>11</td>
<td>9</td>
<td>0.30</td>
<td></td>
</tr>
<tr>
<td>Stage 1 duration in minutes</td>
<td>360±30.6</td>
<td>309±20.13</td>
<td>0.24</td>
<td></td>
</tr>
<tr>
<td>Satge 2 duration in minutes</td>
<td>24.47±10.3</td>
<td>23.26±9.1</td>
<td>0.63</td>
<td></td>
</tr>
<tr>
<td>Stage 3 duration in minutes</td>
<td>8.5±3.9</td>
<td>8.6±4.1</td>
<td>0.73</td>
<td></td>
</tr>
<tr>
<td>Birth weight in gms</td>
<td>2912.2±325.06</td>
<td>3000.4±388.3</td>
<td>0.73</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2:** Comparison of hemoglobin and hematocrit and blood loss between the groups

<table>
<thead>
<tr>
<th></th>
<th>N=100</th>
<th>Study group N=50</th>
<th>Control group N=50</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-delivery Hb (gms/dl)</td>
<td>12.1±0.12</td>
<td>12.3±0.11</td>
<td>0.27</td>
<td></td>
</tr>
<tr>
<td>Post-delivery Hb (gms/dl)</td>
<td>11.4±0.89</td>
<td>10.5±0.73</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>Pre-delivery PCV</td>
<td>37.07±0.36</td>
<td>37.64±0.38</td>
<td>0.28</td>
<td></td>
</tr>
<tr>
<td>Post-delivery PCV</td>
<td>35.09±2.54</td>
<td>32.24±2.54</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>Difference in Hb (gms/dl)</td>
<td>0.7±0.48</td>
<td>1.7±0.70</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>Difference in PCV</td>
<td>1.6±1.29</td>
<td>5.4±2.33</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>Blood loss(ml)</td>
<td>245±42.19</td>
<td>327±44.96</td>
<td>&lt;0.01</td>
<td></td>
</tr>
</tbody>
</table>

**Discussion**

Tranexamic acid given prophylactically before the surgery has shown to reduce the blood loss, by inhibition of fibrinolysis.8,12 In Obstetrics and Gynecology
tranexamic acid has been used extensively to reduce the blood loss either orally in menorrhagia or during myomectomy or cesarean section. The amount of blood loss and the need of post-operative blood transfusions have come down with the perioperative use of tranexamic acid. There are no serious side effects associated with the use of tranexamic acid. The present study is a observational case control study, conducted from August 2015 to August 2017, in a tertiary care hospital to assess the efficacy of tranexamic acid. An analysis was made for 100 women who underwent normal vaginal delivery where they were divided into 2 groups, one who received tranexamic acid as well as oxytocin and the other group who received only Inj Oxytocin. In this study, the mean estimated blood loss is 245 mL in study group and 327 in control group. There was significant reduction in blood loss with the addition of tranexamic acid. Similarly there was significant difference between Hb and PCV post-delivery between the two groups.

Gungorduk et al. did a randomized trial in 439 patients undergoing normal delivery and there was a significant decrease in blood loss in tranexamic group compared to placebo group. In 2015, Priyankur Roy et al conducted a study to find out the efficacy of tranexamic acid in the reduction of blood loss after delivery. The study found good reduction in blood loss with the use of tranexamic acid. A study by Vijayalaxmi Raghavendra Gobbur et al found that tranexamic acid reduces blood loss during cesarean section. Though there are concerns about thrombosis in a study about thrombosis with the use tranexamic acid, we did not observe any side effects associated with tranexamic acid.

Many studies have also proven less blood loss during cesarean section with the use of tranexamic acid. Use of tranexamic acid thus would also reduce blood loss in patients undergoing cesarean section.

There was significant decrease in blood loss when tranexamic acid was used in our study. Use of tranexamic acid in third stage labor would thus help in reducing blood loss. Postpartum bleeding is the commonest cause of maternal morbidity. Tranexamic acid is a readily available and inexpensive drug. Hence its use should be encouraged to reduce blood loss. There was no side effects with the use of tranexamic acid in our study. Larger studies involving larger number of women are needed to evaluate the efficacy of tranexamic acid. Current study involved only a group of 100 women.

**Conclusion**

From our study its clear that use of tranexamic acid would help to reduce blood loss during delivery. It’s a cheap and readily available drug. Its use along with oxytocics would help in reduce blood loss during delivery. Hemorrhage being the commonest cause of maternal mortality its use would help a long way in preventing maternal mortality due to bleeding.

**References**


How to cite this article: Jayaraman N.M, Somu K. The effect of tranexamic acid on blood loss after vaginal delivery. *Indian J Obstet Gynecol Res.* 2018;5(4):559-562.